Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab + Pembrolizumab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT03650764Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- May 2019
- Primary completion
- May 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ramucirumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Recommended Phase 2 Dose at 2.5 months and Objective Response Rate at 162 days. Started May 2019; status: completed.
02
Drugs
ramucirumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03650764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03650764.